Pharma

For those undergoing intravitreal injections (and there are about 22 million of these performed yearly worldwide), a common complaint is that the speculum is uncomfortable,…

Imagine a world where you could use as much preservative as you needed in a prescription eye drop without ever having to worry it would…

CorneaGen’s approach to treating corneal blindness is to prevent it from ever occurring, said Monty Montoya, president and CEO, who added no other organization has…

Days after the U.S. Food and Drug Administration placed a partial hold on RGX-314, RegenxBio (NASDAQ: RGNX) lead gene therapy agent, the company initially outlined…

Oyster Point Pharma is now officially listed on the Nasdaq Global Market under “OYST.” Initial share pricing was $16; to date the stock’s high has…

While Novartis’ recently approved Beovu soaked up a lot of the buzz in the retina space at the American Academy of Ophthalmology, reports of early…

What a difference a day (or so) makes. On Oct. 10, the day of the Ophthalmic Innovation Summit, Aerie Pharmaceuticals’ stock closed at $17.72. The…

CHICAGO – The extensive, intensive public and private investment in the retinal space will fill the day next Thursday, July 25, at the OIS@ASRS meeting,…

In July 2018 Ocular Therapeutix re-submitted its New Drug Application for Dextenza to the Food and Drug Administration. At that time, Scott Corning, the company’s…

VANCOUVER – Novartis is one of the world’s largest ophthalmic pharmaceutical companies, with $4.6 billion in assets as part of the Medicines division, yet some…

VANCOUVER – Leave it to ARVO 2019 – the Association for Research in Vision and Ophthalmology – to keep attendees waiting until mid-evening to hear…